
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 28 years ago
Participating Facultyover 28 years ago
Obesity Management: A Comprehensive Planover 28 years ago
Clinical Efficacy and Safety of Antiobesity Agentsover 28 years ago
Weight Management Partnership: MCOs and Employersover 28 years ago
Selected Abstractsover 28 years ago
CME/CPE Quizover 28 years ago
Bibliography





